Bambuterol
From Wikipedia, the free encyclopedia
|
Bambuterol
|
|
| Systematic (IUPAC) name | |
| {3-(dimethylcarbamoyloxy)-5-[1-hydroxy-2-(tert-butylamino) ethyl]phenyl} N,N-dimethylcarbamate |
|
| Identifiers | |
| CAS number | |
| ATC code | R03 |
| PubChem | |
| Chemical data | |
| Formula | C18H29N3O5 |
| Mol. mass | 367.44 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 20% |
| Metabolism | Hepatic, extensive Further metabolized to terbutaline by plasma cholinesterase |
| Half life | 13 hours (bambuterol) 21 hours (terbutaline) |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
Unknown |
| Legal status |
℞ Prescription only |
| Routes | Oral |
Bambuterol (INN, marketed by AstraZeneca under the trade names Bambec and Oxeol) is a long acting beta-adrenoceptor agonist used in the treatment of asthma. It is a prodrug of terbutaline.
|
||||||||||||||||||||||||||

